Sd101

https://www.ncbi.nlm.nih.gov › pmc › articles
To determine whether SD 101 a Toll like receptor 9 agonist potentiates the antitumor activity of anti PD 1 antibodies in patients with anti PD 1 PD L1 na ve recurrent metastatic head and neck squamous cell carcinoma HNSCC Patients with PD 1

https://www.alldatasheet.com › datasheet-pdf › pdf › DIODES
Part SD101 Download File Size 57Kbytes Page 2 Pages Description SCHOTTKY BARRIER DIODE Manufacturer Diodes Incorporated

https://pubmed.ncbi.nlm.nih.gov
Purpose To determine whether SD 101 a Toll like receptor 9 agonist potentiates the antitumor activity of anti PD 1 antibodies in patients with anti PD 1 PD L1 na ve recurrent metastatic head and neck squamous cell carcinoma HNSCC Patients and methods Patients with PD 1 Ab na ve HNSCC received either 2 mg SD 101 injected in one to four

https://ascopubs.org › doi
Background I SPY 2 is a multicenter phase 2 trial using response adaptive randomization within molecular subtypes defined by receptor status and MammaPrint MP risk to evaluate novel agents as neoadjuvant therapy for women with high risk breast cancer SD 101 is an investigational Toll like receptor 9 TLR9 agonist CpG C class oligodeoxynucleotide that

https://ashpublications.org › blood › article
Introduction Prior studies have shown preliminary clinical efficacy in combining CpG ODN with radiation therapy XRT to patients with indolent B cell lymphoma We report interim Phase 1 2 data of combination XRT and SD 101 a synthetic class C CpG ODN TLR9 agonist selected for the strong induction of type I interferon

https://trisaluslifesci.com › candidate-nelitolimod
TriSalus is investigating nelitolimod also known as SD 101 as a therapeutic candidate to re activate the immune system within the liver and pancreas and to enable deeper and more durable responses to other immunotherapeutics e g checkpoint inhibitors resulting in

https://aacrjournals.org › cancerdiscovery › article
PD 1 inhibitors are approved for treating advanced melanoma but resistance has been observed This phase Ib trial evaluated intratumoral SD 101 a synthetic CpG oligonucleotide that stimulates Toll like receptor 9 TLR9 in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma

https://www.researchgate.net › publication
Antoni Ribas et al demonstrated that SD101 a TLR9 agonist significantly improved the response to systemic Pembrolizumab immunotherapy in patients with advanced melanoma

https://investors.dynavax.com › news-releases › news...
SD 101 is a proprietary investigational second generation Toll like receptor 9 TLR9 agonist CpG C class oligodeoxynucleotide TriSalus plans to further develop SD 101 as an oncology therapeutic